Editas Medicine (EDIT) Posts Q1 GAAP Loss of 80c/Share

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.80), which may not compare with the analyst estimate of ($0.30). Revenue for the quarter came in at $805 thousand versus the consensus estimate of $1.08 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• Goldman Sachs updates view on protein markets ahead of earnings
• XP Inc. (XP) Tops Q2 EPS by 8c